Biotechnology
Compare Stocks
5 / 10Stock Comparison
XAGE vs WELL vs VTR vs HIMS vs TDOC
Revenue, margins, valuation, and 5-year total return — side by side.
REIT - Healthcare Facilities
REIT - Healthcare Facilities
Medical - Equipment & Services
Medical - Healthcare Information Services
XAGE vs WELL vs VTR vs HIMS vs TDOC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Biotechnology | REIT - Healthcare Facilities | REIT - Healthcare Facilities | Medical - Equipment & Services | Medical - Healthcare Information Services |
| Market Cap | $7M | $149.25B | $41.15B | $6.63B | $1.26B |
| Revenue (TTM) | $1M | $11.63B | $6.13B | $2.35B | $2.51B |
| Net Income (TTM) | $-6M | $1.43B | $260M | $128M | $-171M |
| Gross Margin | 54.6% | 39.1% | -4.3% | 69.7% | 65.6% |
| Operating Margin | -401.0% | 4.4% | 13.4% | 4.6% | -7.6% |
| Forward P/E | — | 78.4x | 118.0x | 51.5x | — |
| Total Debt | $639K | $21.38B | $13.22B | $1.12B | $1.04B |
| Cash & Equiv. | $157K | $5.03B | $741M | $229M | $781M |
XAGE vs WELL vs VTR vs HIMS vs TDOC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 21 | May 26 | Return |
|---|---|---|---|
| Longevity Health Ho… (XAGE) | 100 | 0.1 | -99.9% |
| Welltower Inc. (WELL) | 100 | 258.5 | +158.5% |
| Ventas, Inc. (VTR) | 100 | 156.7 | +56.7% |
| Hims & Hers Health,… (HIMS) | 100 | 340.4 | +240.4% |
| Teladoc Health, Inc. (TDOC) | 100 | 5.5 | -94.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: XAGE vs WELL vs VTR vs HIMS vs TDOC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
XAGE ranks third and is worth considering specifically for growth.
- 139.4% revenue growth vs TDOC's -1.5%
WELL carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.
- 223.1% 10Y total return vs HIMS's 161.9%
- Lower volatility, beta 0.13, Low D/E 49.5%, current ratio 5.34x
- 12.3% margin vs XAGE's -393.6%
- 1.3% yield, 2-year raise streak, vs VTR's 2.1%, (3 stocks pay no dividend)
VTR is the clearest fit if your priority is income & stability and defensive.
- Dividend streak 1 yrs, beta 0.01, yield 2.1%
- Beta 0.01, yield 2.1%, current ratio 0.96x
- Beta 0.01 vs HIMS's 2.40, lower leverage
HIMS is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 59.0%, EPS growth -3.8%, 3Y rev CAGR 64.5%
- Lower P/E (51.5x vs 118.0x)
- 6.0% ROA vs XAGE's -173.9%, ROIC 10.7% vs -38.0%
Among these 5 stocks, TDOC doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 139.4% revenue growth vs TDOC's -1.5% | |
| Value | Lower P/E (51.5x vs 118.0x) | |
| Quality / Margins | 12.3% margin vs XAGE's -393.6% | |
| Stability / Safety | Beta 0.01 vs HIMS's 2.40, lower leverage | |
| Dividends | 1.3% yield, 2-year raise streak, vs VTR's 2.1%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +42.7% vs XAGE's -92.6% | |
| Efficiency (ROA) | 6.0% ROA vs XAGE's -173.9%, ROIC 10.7% vs -38.0% |
XAGE vs WELL vs VTR vs HIMS vs TDOC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
XAGE vs WELL vs VTR vs HIMS vs TDOC — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
VTR leads in 2 of 6 categories
TDOC leads 1 • HIMS leads 1 • WELL leads 1 • XAGE leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
VTR leads this category, winning 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
WELL is the larger business by revenue, generating $11.6B annually — 7980.8x XAGE's $1M. WELL is the more profitable business, keeping 12.3% of every revenue dollar as net income compared to XAGE's -3.9%. On growth, XAGE holds the edge at +19.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1M | $11.6B | $6.1B | $2.3B | $2.5B |
| EBITDAEarnings before interest/tax | -$6M | $2.8B | $2.3B | $164M | $42M |
| Net IncomeAfter-tax profit | -$6M | $1.4B | $260M | $128M | -$171M |
| Free Cash FlowCash after capex | -$4M | $2.5B | $1.4B | $73M | $251M |
| Gross MarginGross profit ÷ Revenue | +54.6% | +39.1% | -4.3% | +69.7% | +65.6% |
| Operating MarginEBIT ÷ Revenue | -4.0% | +4.4% | +13.4% | +4.6% | -7.6% |
| Net MarginNet income ÷ Revenue | -3.9% | +12.3% | +4.2% | +5.5% | -6.8% |
| FCF MarginFCF ÷ Revenue | -2.6% | +21.9% | +22.4% | +3.1% | +10.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +19.8% | +40.3% | +22.0% | +28.4% | -2.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -4.9% | +22.5% | 0.0% | -27.3% | +32.1% |
Valuation Metrics
TDOC leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
At 50.3x trailing earnings, HIMS trades at a 69% valuation discount to VTR's 160.3x P/E. On an enterprise value basis, TDOC's 15.1x EV/EBITDA is more attractive than WELL's 66.4x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $7M | $149.2B | $41.1B | $6.6B | $1.3B |
| Enterprise ValueMkt cap + debt − cash | $7M | $165.6B | $53.6B | $7.5B | $1.5B |
| Trailing P/EPrice ÷ TTM EPS | -0.64x | 153.25x | 160.26x | 50.32x | -6.11x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 78.42x | 118.01x | 51.51x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 66.40x | 24.31x | 42.68x | 15.13x |
| Price / SalesMarket cap ÷ Revenue | 133.03x | 13.99x | 7.05x | 2.82x | 0.50x |
| Price / BookPrice ÷ Book value/share | — | 3.35x | 3.18x | 12.25x | 0.89x |
| Price / FCFMarket cap ÷ FCF | — | 52.41x | 31.25x | 89.61x | 4.40x |
Profitability & Efficiency
HIMS leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
HIMS delivers a 23.7% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-103 for XAGE. WELL carries lower financial leverage with a 0.49x debt-to-equity ratio, signaling a more conservative balance sheet compared to HIMS's 2.07x. On the Piotroski fundamental quality scale (0–9), WELL scores 7/9 vs HIMS's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -103.5% | +3.5% | +2.1% | +23.7% | -12.4% |
| ROA (TTM)Return on assets | -173.9% | +2.3% | +1.0% | +6.0% | -5.9% |
| ROICReturn on invested capital | -38.0% | +0.5% | +2.5% | +10.7% | -11.5% |
| ROCEReturn on capital employed | -47.5% | +0.6% | +3.2% | +10.9% | -10.0% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 | 6 | 4 | 6 |
| Debt / EquityFinancial leverage | — | 0.49x | 1.05x | 2.07x | 0.75x |
| Net DebtTotal debt minus cash | $481,854 | $16.3B | $12.5B | $892M | $259M |
| Cash & Equiv.Liquid assets | $157,139 | $5.0B | $741M | $229M | $781M |
| Total DebtShort + long-term debt | $638,993 | $21.4B | $13.2B | $1.1B | $1.0B |
| Interest CoverageEBIT ÷ Interest expense | -293.50x | 0.26x | 1.40x | — | -8.76x |
Total Returns (Dividends Reinvested)
WELL leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in WELL five years ago would be worth $30,234 today (with dividends reinvested), compared to $11 for XAGE. Over the past 12 months, WELL leads with a +42.7% total return vs XAGE's -92.6%. The 3-year compound annual growth rate (CAGR) favors WELL at 42.5% vs XAGE's -89.8% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +6.4% | +14.3% | +12.6% | -23.2% | -1.3% |
| 1-Year ReturnPast 12 months | -92.6% | +42.7% | +33.9% | -51.0% | +1.5% |
| 3-Year ReturnCumulative with dividends | -99.9% | +189.5% | +94.2% | +116.6% | -73.3% |
| 5-Year ReturnCumulative with dividends | -99.9% | +202.3% | +74.8% | +137.6% | -95.4% |
| 10-Year ReturnCumulative with dividends | -99.9% | +223.1% | +65.0% | +161.9% | -41.1% |
| CAGR (3Y)Annualised 3-year return | -89.8% | +42.5% | +24.8% | +29.4% | -35.6% |
Risk & Volatility
VTR leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
VTR is the less volatile stock with a 0.01 beta — it tends to amplify market swings less than HIMS's 2.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. VTR currently trades 97.8% from its 52-week high vs XAGE's 3.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.86x | 0.13x | 0.01x | 2.40x | 1.91x |
| 52-Week HighHighest price in past year | $8.27 | $219.59 | $88.50 | $70.43 | $9.77 |
| 52-Week LowLowest price in past year | $0.23 | $142.65 | $61.76 | $13.74 | $4.40 |
| % of 52W HighCurrent price vs 52-week peak | +3.9% | +97.0% | +97.8% | +36.4% | +71.2% |
| RSI (14)Momentum oscillator 0–100 | 48.5 | 60.2 | 56.2 | 54.5 | 74.1 |
| Avg Volume (50D)Average daily shares traded | 1K | 2.6M | 3.4M | 34.9M | 5.5M |
Analyst Outlook
Evenly matched — WELL and VTR each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: WELL as "Buy", VTR as "Buy", HIMS as "Hold", TDOC as "Hold". Consensus price targets imply 15.6% upside for HIMS (target: $30) vs 4.9% for VTR (target: $91). For income investors, VTR offers the higher dividend yield at 2.15% vs WELL's 1.30%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Hold | Hold |
| Price TargetConsensus 12-month target | — | $226.50 | $90.80 | $29.67 | $7.58 |
| # AnalystsCovering analysts | — | 34 | 32 | 19 | 42 |
| Dividend YieldAnnual dividend ÷ price | — | +1.3% | +2.1% | — | — |
| Dividend StreakConsecutive years of raises | — | 2 | 1 | — | — |
| Dividend / ShareAnnual DPS | — | $2.76 | $1.86 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +1.4% | 0.0% |
VTR leads in 2 of 6 categories (Income & Cash Flow, Risk & Volatility). TDOC leads in 1 (Valuation Metrics). 1 tied.
XAGE vs WELL vs VTR vs HIMS vs TDOC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is XAGE or WELL or VTR or HIMS or TDOC a better buy right now?
For growth investors, Hims & Hers Health, Inc.
(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -1. 5% for Teladoc Health, Inc. (TDOC). Hims & Hers Health, Inc. (HIMS) offers the better valuation at 50. 3x trailing P/E (51. 5x forward), making it the more compelling value choice. Analysts rate Welltower Inc. (WELL) a "Buy" — based on 34 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — XAGE or WELL or VTR or HIMS or TDOC?
On trailing P/E, Hims & Hers Health, Inc.
(HIMS) is the cheapest at 50. 3x versus Ventas, Inc. at 160. 3x. On forward P/E, Hims & Hers Health, Inc. is actually cheaper at 51. 5x.
03Which is the better long-term investment — XAGE or WELL or VTR or HIMS or TDOC?
Over the past 5 years, Welltower Inc.
(WELL) delivered a total return of +202. 3%, compared to -99. 9% for Longevity Health Holdings Inc. (XAGE). Over 10 years, the gap is even starker: WELL returned +223. 1% versus XAGE's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — XAGE or WELL or VTR or HIMS or TDOC?
By beta (market sensitivity over 5 years), Ventas, Inc.
(VTR) is the lower-risk stock at 0. 01β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 25184% more volatile than VTR relative to the S&P 500. On balance sheet safety, Welltower Inc. (WELL) carries a lower debt/equity ratio of 49% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — XAGE or WELL or VTR or HIMS or TDOC?
By revenue growth (latest reported year), Hims & Hers Health, Inc.
(HIMS) is pulling ahead at 59. 0% versus -1. 5% for Teladoc Health, Inc. (TDOC). On earnings-per-share growth, the picture is similar: Ventas, Inc. grew EPS 184. 2% year-over-year, compared to -11. 5% for Welltower Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — XAGE or WELL or VTR or HIMS or TDOC?
Welltower Inc.
(WELL) is the more profitable company, earning 8. 8% net margin versus -206. 1% for Longevity Health Holdings Inc. — meaning it keeps 8. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VTR leads at 14. 2% versus -99. 3% for XAGE. At the gross margin level — before operating expenses — XAGE leads at 87. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is XAGE or WELL or VTR or HIMS or TDOC more undervalued right now?
On forward earnings alone, Hims & Hers Health, Inc.
(HIMS) trades at 51. 5x forward P/E versus 118. 0x for Ventas, Inc. — 66. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HIMS: 15. 6% to $29. 67.
08Which pays a better dividend — XAGE or WELL or VTR or HIMS or TDOC?
In this comparison, VTR (2.
1% yield), WELL (1. 3% yield) pay a dividend. XAGE, HIMS, TDOC do not pay a meaningful dividend and should not be held primarily for income.
09Is XAGE or WELL or VTR or HIMS or TDOC better for a retirement portfolio?
For long-horizon retirement investors, Ventas, Inc.
(VTR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 01), 2. 1% yield). Teladoc Health, Inc. (TDOC) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VTR: +65. 0%, TDOC: -41. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between XAGE and WELL and VTR and HIMS and TDOC?
These companies operate in different sectors (XAGE (Healthcare) and WELL (Real Estate) and VTR (Real Estate) and HIMS (Healthcare) and TDOC (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: XAGE is a small-cap quality compounder stock; WELL is a mid-cap high-growth stock; VTR is a mid-cap high-growth stock; HIMS is a small-cap high-growth stock; TDOC is a small-cap quality compounder stock. WELL, VTR pay a dividend while XAGE, HIMS, TDOC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.